Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed’s Next Move
May 1, 8:03 AM
Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts.
Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On ‘Blindness & Regeneration’
May 1, 8:00 AM
Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of
FDA Approves Merck’s Keytruda Combined With Seagen/Astellas’s Padcev For Advanced Urothelial Cancer
April 4, 9:08 AM
The FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with Astellas Pharma Inc (OTC:ALMPF) & Seagen Inc’s (NASDAQ:SGEN) Padcev (enfortumab vedotin-ejfv) locally…
Japanese Government Urges China To Release Astellas Pharma’s Employee
March 27, 7:34 AM
The Japanese government is reportedly seeking the release of an employee of Japanese pharma company Astellas Pharma Inc (OTC: ALPMF), detained by Chinese authorities.
The reasons why the person was detained are still unknown.
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
March 17, 10:17 AM
Pfizer Inc (NYSE:PFE) and Astellas Pharma Inc (OTC:ALPMY) released topline results from the Phase 3 EMBARK trial evaluating Xtandi (enzalutamide) in non-metastatic hormone-sensitive…
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
March 13, 1:18 PM
Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…
Super Bowl Commercials 2023: The Complete List Of Super Bowl LVII Ads And The Companies Behind Them
February 13, 3:17 PM
Super Bowl LVII aired Sunday Feb. 12, 2023 and featured dozens of commercials advertising products and showcasing new movies and television shows. The commercials also featured many celebrity cameos and several reunions. Here’s a look at the complete list.
Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts
January 31, 2:15 PM
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…
Astellas’ Menopause Drug Under FDA Review
August 18, 12:04 PM
The FDA accepted Astellas Pharma Inc’s (OTC:ALPMF) menopause treatment for approval five months after the therapy hit a speed bump in…